| | | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
|---|
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | R | S | T | U | V | X | Z |
| L | | IP | CI | A | Subutex 0,4 mg | 7 Tablet(s) | 2.97 | 12.45 | 10 % | | Sublingual tablets: Buprenorphinum | Indivior Schweiz AG | A+ / SL / SO | FB | | G |  |
| L | | IP | CI | A | Subutex 2 mg | 28 Tablet(s) | 25.23 | 43.55 | 10 % | | Sublingual tablets: Buprenorphinum 2 mg | Indivior Schweiz AG | A+ / SL / SO | FB | | G | |
| L | | IP | CI | A | Subutex 8 mg | 28 Tablet(s) | 90.60 | 113.85 | 10 % | | Sublingual tablets: Buprenorphinum 8 mg | Indivior Schweiz AG | A+ / SL / SO | FB | | G | |
| L | | IP | CI | A | Seresta | 20 Tablet(s) | 1.96 | 11.35 | 10 % | | Tablets: Oxazepamum 15 mg | Viatris Pharma GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | A | Seresta | 50 Tablet(s) | 4.26 | 13.85 | 10 % | | Tablets: Oxazepamum 15 mg | Viatris Pharma GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | A | Sevre-Long 30 mg | 30 Capsule(s) | 20.28 | 38.45 | 10 % | | Delayed release capsules: Morphini Sulfas Pentahydricus 30 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| L | | IP | CI | A | Sevre-Long 60 mg | 30 Capsule(s) | 33.27 | 52.60 | 10 % | | Delayed release capsules: Morphini Sulfas Pentahydricus 60 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| L | | IP | CI | A | Sevre-Long 120 mg | 30 Capsule(s) | 54.52 | 75.70 | 10 % | | Delayed release capsules: Morphini Sulfas Pentahydricus 120 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| L | | IP | CI | A | Sevre-Long 200 mg - T | 30 Capsule(s) | 60.92 | 82.65 | 10 % | | Delayed release capsules: Morphini Sulfas Pentahydricus 200 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| | | IP | CI | A | Sevredol 10 mg | 20 Tablet(s) | 6.99 | 16.85 | 10 % | | Coated tablets: Morphini Sulfas Pentahydricus 10 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| L | | IP | CI | A | Seresta forte | 20 Tablet(s) | 4.79 | 14.45 | 10 % | | Tablets: Oxazepamum 50 mg | Viatris Pharma GmbH | B / SL | FB | | G | |
| L | | IP | CI | A | Seresta forte | 100 Tablet(s) | 18.58 | 36.60 | 10 % | | Tablets: Oxazepamum 50 mg | Viatris Pharma GmbH | B / SL | FB | | G | |
| | | IP | CI | A | Stilnox CR 6.25 mg | 14 Tablet(s) | 1.91 | 11.30 | 10 % | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B / SL | FB | | G | |
| | | IP | CI | A | Stilnox CR 12.5 mg | 14 Tablet(s) | 3.23 | 12.75 | 10 % | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B / SL | FB | | G | |
| | | IP | | A | Sufenta | 5 1 ampoule(s) à 2 ml | PR | PR | k.A. | | Injection solution: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | | A | Sufenta | 5 1 ampoule(s) à 10 ml | PR | PR | k.A. | | Injection solution: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | | A | Sufenta forte | 5 1 ampoule(s) à 1 ml | PR | PR | k.A. | | Injection solution: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | | A | Sufenta forte | 5 1 ampoule(s) à 5 ml | PR | PR | k.A. | | Injection solution: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | CI | A | Subutex 0,4 mg | 28 Tablet(s) | PR | PR | k.A. | | Sublingual tablets: Buprenorphinum | Indivior Schweiz AG | A+ | FB | | G | |
| | | IP | CI | A | Subutex 2 mg | 7 Tablet(s) | 7.04 | 16.30 | k.A. | | Sublingual tablets: Buprenorphinum 2 mg | Indivior Schweiz AG | A+ | FB | | G | |
| | | IP | CI | A | Subutex 8 mg | 7 Tablet(s) | 24.58 | 44.60 | k.A. | | Sublingual tablets: Buprenorphinum 8 mg | Indivior Schweiz AG | A+ | FB | | G | |
| | | IP | CI | A | Stilnox ‐ I - T | 10 Tablet(s) | 2.78 | 7.30 | k.A. | | Divitabs: Zolpidemi Tartras 10 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
| | | IP | CI | A | Stilnox ‐ I - T | 30 Tablet(s) | 7.20 | 16.45 | k.A. | | Divitabs: Zolpidemi Tartras 10 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
| | | IP | CI | A | Stilnox CR 6.25 mg | 7 Tablet(s) | PR | PR | 10 % | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
| | | IP | CI | A | Stilnox CR 6.25 mg | 28 Tablet(s) | 3.41 | 12.95 | k.A. | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
| | | IP | CI | A | Stilnox CR 12.5 mg | 7 Tablet(s) | PR | PR | 10 % | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
| | | IP | CI | A | Stilnox CR 12.5 mg | 28 Tablet(s) | 5.77 | 15.50 | k.A. | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
